Renal Immunology

 In the kidney, toxic waste products of metabolism and salt are removed from the blood. In addition, the kidney have functions as a size-selective filter that retains molecules above -50 kDa in blood. Nephrotic syndrome comprise symptoms of proteina, hypoalbuminemia, and edema, which are caused by the disruption of kidney induced for some reasons. The mechanisms of nephrotic syndrome are still unclear, although the immune system might be involved in present symptoms of nephrotic syndrome.
Recent studies demonstrated that the Rituximab (anti-human CD20 antibody) is a highly effective treatment for nephrotic syndrome. CD20 is widely expressed on B cells. Therefore, B cells might be involved in present symptoms of nephrotic syndrome.
We want to clarify the involvement of B cells on nephrotic syndrome, through the immune monitoring for pediatric patients with nephrotic syndrome who treat with the rituximab.
We are studying this research project in collaboration with Dr. Seiji Tanaka, Department of Pediatrics and child health, Kurume University school of Medicine. In addition, this research project is supported by a Grant-in Aid for Scientific Research (C).




・がん免疫に関する研究 Cancer Immunology



Yokomine, M., Matsueda, S., Kawano, K., Sasada, T., Fukui, A., Yamashita, T., Komatsu, N., Shichijo, S., Tasaki, K., Matsukuma, K., Itoh, K., Kamura, T., Ushijima, K.
Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females
(2017) Exp. Ther. Med., 13(4), pp. 1500-1505.


Noguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., Ohyama, C., Nasu, Y., Tanaka, M., Moriya, F., Suekane, S., Matsueda, S., Komatsu, N., Sasada, T., Yamada, A., Kakuma, T., Itoh, K.
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
(2016) Clin. Cancer Res., 22(1), p. 54-60.

Iwasa, S., Yamada, Y., Heike, Y., Shoji, H., Honma, Y., Komatsu, N., Matsueda, S., Yamada, A., Morita, M., Yamaguchi, R., Tanaka, N., Kawahara, A., Kage, M., Shichijo, S., Sasada, T., Itoh, K.
Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
(2016) Cancer Sci., 107(5), pp. 590-600.


Yamada, T., Terazaki, Y., Sakamoto, S., Yoshiyama, K., Matsueda, S., Komatsu, N., Waki, K., Yamada, A., Kawahara, A., Kage, M., Sugawara, S., Yamashita, Y., Sasada, T., Takamori, S., Itoh, K.
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens
(2015) Int. J. Oncol., 46(1) pp. 55-62.

Noguchi, M., Arai, G., Matsumoto, K., Naito, S., Moriya, F., Suekane, S., Komatsu, N., Matsueda, S., Sasada, T., Yamada, A., Kakuma, T., Itoh, K.
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression
(2015) Cancer Immunol. Immunother., 64(4), pp. 493-505.

Araki, H., Pang, X., Komatsu, N., Soejima, M., Miyata, N., Takaki, M., Muta, S., Sasada, T., Noguchi, M., Koda, Y., Itoh, K., Kuhara, S., Tashiro, K.
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients
(2015) Cancer Immunol. Immunother., 64(12), pp. 1565-1573.

Yutani, S., Ueshima, K., Abe, K., Ishiguro, A., Eguchi, J., Matsueda, S., Komatsu, N., Shichijo, S., Yamada, A., Itoh, K., Sasada, T., Kudo, M., Noguchi, M.
Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
(2015) J. Immunol. Res., 2015, pp. 473909.


Kibe, S., Yutani, S., Motoyama, S., Nomura, T., Tanaka, N., Kawahara, A., Yamaguchi, T., Matsueda, S., Komatsu, N., Miura, M., Hinai, Y., Hattori, S., Yamada, A., Kage, M., Itoh, K., Akagi, Y., Sasada, T.
Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer
(2014) Cancer Immunol. Res., 2(12), pp. 1154-1162.

Waki, K., Yamada, T., Yoshiyama, K., Terazaki, Y., Sakamoto, S., Matsueda, S., Komatsu, N., Sugawara, S., Takamori, S., Itoh, K., Yamada, A.
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
(2014) Cancer Sci., 105(10) pp. 1229-1235.

Azuma, K., Komatsu, N.,Hattori, S.,Matsueda, S., Kawahara, A., Sasada, T., Itoh, K., Hoshino, T.
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib
(2014) PLoS One, 9(1), pp. e86667.

Soejima, M., Sagata, N., Komatsu, N., Sasada, T., Kawaguchi, A., Itoh, K., Koda, Y.
Genetic factors associated with serum haptoglobin level in a Japanese population
(2014) Clinica Chimica Acta, 433, pp. 54-57.


Matsueda, S., Komatsu, N., Kusumoto, K., Koga, S., Yamada, A., Kuromatsu, R., Yamada, S., Seki, R., Yutani, S., Shichijo, S., Mine, T., Fukuda, T., Okamura, T., Okuda, S., Sata, M., Honda, J., Kaji, M., Itoh, K., Sasada, T.
Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases
(2013) Developmental and Comparative Immunology, 41 (1), pp. 68-76.

Yutani, S., Komatsu, N., Yoshitomi, M., Matsueda, S., Yonemoto, K., Mine, T., Noguchi, M., Ishihara, Y., Yamada, A., Itoh, K., Sasada, T.
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients
(2013) Oncology Reports, 30 (3), pp. 1094-1100.

Yutani, S., Komatsu, N., Matsueda, S., Yoshitomi, M., Shirahama, T., Yamada, A., Itoh, K., Sasada, T.
Juzentaihoto failed to augment antigen-specific immunity but prevented deterioration of patients' conditions in advanced pancreatic cancer under personalized peptide vaccine
(2013) Evidence-based Complementary and Alternative Medicine, 2013, art. no. 981717, .

Pang, X., Tashiro, K., Eguchi, R., Komatsu, N., Sasada, T., Itoh, K., Kuhara, S.
Haptoglobin proved a prognostic biomarker in peripheral blood of patients with personalized peptide vaccinations for advanced castration-resistant prostate cancer
(2013) Bioscience, Biotechnology and Biochemistry, 77 (4), pp. 766-770.

Komatsu, N., Jackson, H.M., Chan, K.-F., Oveissi, S., Cebon, J., Itoh, K., Chen, W.
Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein
(2013) Molecular Immunology, 54 (3-4), pp. 465-471.

Komatsu, N., Matsueda, S., Noguchi, M., Yamada, A., Noguchi, M., Itoh, K., Sasada, T.
Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer
(2013) Molecular Vaccines, Part IV, pp. 361-369.

テーラーメイドペプチドワクチン ─個人の免疫記憶に基づくワクチン選択と治療
(2013) 実験医学増刊号, 31 (12), pp. 160-162.